Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer
Vicarious Surgical (NYSE: RBOT) has appointed Sarah Romano as Chief Financial Officer, effective April 1, 2025. Romano brings decades of financial leadership experience in capital markets, particularly in the healthcare sector. She previously served as CFO of Entero Therapeutics, where she managed financial strategy and executed product in-licensing partnerships.
At her former position as CFO of Kiora Pharmaceuticals, Romano secured over $50 million in funding and led M&A activities. Her expertise includes financial strategy, operations, compliance, budget reviews, forecasting, internal controls oversight, and SEC reporting. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT) ha nominato Sarah Romano come Chief Financial Officer, a partire dal 1 aprile 2025. Romano porta con sé decenni di esperienza nella leadership finanziaria nei mercati dei capitali, in particolare nel settore sanitario. In precedenza, ha ricoperto il ruolo di CFO presso Entero Therapeutics, dove ha gestito la strategia finanziaria e ha realizzato partnership per l'in-licensing di prodotti.
Nella sua precedente posizione come CFO di Kiora Pharmaceuticals, Romano ha ottenuto oltre 50 milioni di dollari in finanziamenti e ha guidato attività di fusione e acquisizione. La sua esperienza include strategia finanziaria, operazioni, conformità, revisione del budget, previsioni, supervisione dei controlli interni e reporting SEC. Romano ha conseguito un Master in Contabilità presso il Boston College e una laurea in Contabilità presso il College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT) ha nombrado a Sarah Romano como Directora Financiera, con efecto a partir del 1 de abril de 2025. Romano aporta décadas de experiencia en liderazgo financiero en los mercados de capitales, especialmente en el sector de la salud. Anteriormente, se desempeñó como CFO de Entero Therapeutics, donde gestionó la estrategia financiera y ejecutó asociaciones de licencias de productos.
En su puesto anterior como CFO de Kiora Pharmaceuticals, Romano aseguró más de 50 millones de dólares en financiamiento y lideró actividades de fusiones y adquisiciones. Su experiencia incluye estrategia financiera, operaciones, cumplimiento, revisión de presupuestos, pronósticos, supervisión de controles internos e informes a la SEC. Romano posee un máster en Contabilidad por el Boston College y una licenciatura en Contabilidad por el College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT)는 Sarah Romano를 2025년 4월 1일부터 최고재무책임자(CFO)로 임명했습니다. 로마노는 특히 의료 분야에서 자본 시장의 재무 리더십 경험을 수십 년 동안 쌓아왔습니다. 그녀는 이전에 Entero Therapeutics의 CFO로 재직하며 재무 전략을 관리하고 제품 라이센싱 파트너십을 실행했습니다.
이전 Kiora Pharmaceuticals의 CFO로서 로마노는 5천만 달러 이상의 자금을 확보하고 인수합병 활동을 이끌었습니다. 그녀의 전문 분야에는 재무 전략, 운영, 준수, 예산 검토, 예측, 내부 통제 감독 및 SEC 보고가 포함됩니다. 로마노는 보스턴 대학교에서 회계 석사 학위를, Holy Cross College에서 회계 학사 학위를 취득했습니다.
Vicarious Surgical (NYSE: RBOT) a nommé Sarah Romano au poste de Directrice Financière, à compter du 1er avril 2025. Romano apporte des décennies d'expérience en leadership financier sur les marchés des capitaux, notamment dans le secteur de la santé. Auparavant, elle a été CFO d'Entero Therapeutics, où elle a géré la stratégie financière et exécuté des partenariats de licence de produits.
Dans son précédent poste de CFO de Kiora Pharmaceuticals, Romano a sécurisé plus de 50 millions de dollars de financement et a dirigé des activités de fusion et d'acquisition. Son expertise comprend la stratégie financière, les opérations, la conformité, les examens budgétaires, les prévisions, la supervision des contrôles internes et le reporting à la SEC. Romano est titulaire d'un Master en Comptabilité du Boston College et d'une licence en Comptabilité du College of the Holy Cross.
Vicarious Surgical (NYSE: RBOT) hat Sarah Romano zum Chief Financial Officer ernannt, der am 1. April 2025 sein Amt antreten wird. Romano bringt Jahrzehnte an Erfahrung in der finanziellen Führung in den Kapitalmärkten mit, insbesondere im Gesundheitssektor. Zuvor war sie CFO von Entero Therapeutics, wo sie die Finanzstrategie leitete und Produkt-Lizenzpartnerschaften umsetzte.
In ihrer vorherigen Position als CFO von Kiora Pharmaceuticals sicherte Romano über 50 Millionen Dollar an Finanzierung und leitete M&A-Aktivitäten. Ihre Expertise umfasst Finanzstrategie, Betrieb, Compliance, Budgetüberprüfungen, Prognosen, Überwachung interner Kontrollen und SEC-Berichterstattung. Romano hat einen Master-Abschluss in Rechnungswesen vom Boston College und einen Bachelor-Abschluss in Rechnungswesen vom College of the Holy Cross.
- Appointment of experienced CFO with strong healthcare sector background
- New CFO has proven track record in successful fundraising ($50M+)
- Demonstrated expertise in M&A activities and product in-licensing partnerships
- None.
Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development
Ms. Romano will oversee Vicarious Surgical’s financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the healthcare sector, through successful fundraising and M&A initiatives.
Adam Sachs, Co-Founder and Chief Executive Officer of Vicarious Surgical, said: “We are delighted to welcome Sarah to the Vicarious Surgical team. Her exceptional financial strategy acumen makes her an invaluable asset to our company and the ideal partner to lead our finance organization. I'm confident her expertise and strategic vision will be instrumental in driving our financial objectives and overall success.”
Ms. Romano added, “The energy and momentum at Vicarious Surgical is palpable as we approach our first clinical use cases later this year. I'm thrilled to bring my experience to the team and play a key role in ensuring we have the financial strength to achieve our milestones and beyond.”
Most recently, Ms. Romano served as Chief Financial Officer of Entero Therapeutics, where she oversaw financial strategy, operations, and compliance, raising significant funding and successfully executing product in-licensing partnerships. Previously, as Chief Financial Officer of Kiora Pharmaceuticals, Ms. Romano secured over
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical’s Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical’s ability to identify, in-license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical’s financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; Vicarious Surgical’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313275183/en/
Investor Contact
Kaitlyn Brosco
Vicarious Surgical
Kbrosco@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
Source: Vicarious Surgical Inc.
FAQ
When will Sarah Romano start as CFO of Vicarious Surgical (RBOT)?
What is Sarah Romano's track record in fundraising at her previous companies?
What are Sarah Romano's key responsibilities as the new CFO of RBOT?
What is Sarah Romano's educational background?
